Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.

@article{Zoutendijk2011SerumHD,
  title={Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.},
  author={Roeland Zoutendijk and Bettina E Hansen and Anneke J. van Vuuren and Charles A. B. Boucher and Harry L. A. Janssen},
  journal={The Journal of infectious diseases},
  year={2011},
  volume={204 3},
  pages={415-8}
}
Nucleos(t)ide analogues strongly inhibit viral replication in chronic hepatitis B (CHB) infection, but knowledge of their long-term effect on serum hepatitis B surface antigen (HBsAg) levels and HBsAg loss is lacking. Seventy-five CHB patients with virological response (VR) to ETV or TDF were included. HBsAg decline 2 years after VR was most pronounced in HBeAg-positive patients. Age, alanine aminotransferase, and HBeAg loss were associated with HBsAg decline in HBeAg-positive patients… CONTINUE READING